![AbbVie's Humira needs a discount, ICER says, warning Lilly, Sanofi to price with care | Fierce Pharma AbbVie's Humira needs a discount, ICER says, warning Lilly, Sanofi to price with care | Fierce Pharma](https://qtxasset.com/cdn-cgi/image/w=384,h=216,f=auto,fit=crop,g=0.5x0.5/https://qtxasset.com/quartz/qcloud5/media/image/2016-09/humiragood.jpg?VersionId=IMHQKeP3FEsbi1KzkE2Lmb6oS2BKDhtf)
AbbVie's Humira needs a discount, ICER says, warning Lilly, Sanofi to price with care | Fierce Pharma
![AbbVie, Humira among products, companies facing penalty under drug pricing rule | Crain's Chicago Business AbbVie, Humira among products, companies facing penalty under drug pricing rule | Crain's Chicago Business](https://s3-prod.chicagobusiness.com/4423388174_c80ca733ea_o_0.jpg)
AbbVie, Humira among products, companies facing penalty under drug pricing rule | Crain's Chicago Business
![Canadians living with Moderate to Severe Hidradenitis Suppurativa are beginning to have public access to HUMIRA® (Adalimumab) to manage their disease | Markets Insider Canadians living with Moderate to Severe Hidradenitis Suppurativa are beginning to have public access to HUMIRA® (Adalimumab) to manage their disease | Markets Insider](https://mma.prnewswire.com/media/644330/AbbVie_Canada_Canadians_living_with_Moderate_to_Severe_Hidradeni.jpg)
Canadians living with Moderate to Severe Hidradenitis Suppurativa are beginning to have public access to HUMIRA® (Adalimumab) to manage their disease | Markets Insider
![Humira rings up $20.7B in 2021, but AbbVie still mum on post-biosimilar expectations | Fierce Pharma Humira rings up $20.7B in 2021, but AbbVie still mum on post-biosimilar expectations | Fierce Pharma](https://qtxasset.com/quartz/qcloud5/media/image/fiercepharma/1643820639/large.img_.png/large.img_.png?VersionId=Qe.Z8MhPo8.UNbqc4s7d3.fQ8QAisbYS)